Caldwell and PwC Announce Partnership on Canada s Top 40 Under 40® newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
VANCOUVER A swab up the nose and gargling salt water are two of the ways people are now tested for COVID-19 in B.C., but researchers have been working on a fast and non-invasive option that would involve giving a breath sample. Interventional respirologist Dr. Renelle Myers – who works at Vancouver General Hospital and BC Cancer and is also a clinician scientist at the BC Cancer Research Institute – told CTV News Vancouver her team had been preparing to study using breath samples for the early detection of lung cancer. When the pandemic hit, we knew the potential of breath, and thought let s change gears and see if we can diagnose COVID-19 through breath analysis, because it would provide a very rapid, non-invasive way to do it, she said, and added their work in relation to lung cancer will continue.
The Granzyme B (GzmB) enzyme, which accumulates in certain tissues as we age, has been identified as a driver of itchy and sometimes life-threatening autoimmune conditions known as pemphigoid diseases (PDs), which cause blistering and skin erosion below the skin's surface.
The Granzyme B (GzmB) enzyme, which accumulates in certain tissues as we age, has been identified as a driver of itchy and sometimes life-threatening autoimmune conditions known as pemphigoid diseases (PDs), which cause blistering and skin erosion below the skin s surface. New research led by University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has found that a gel containing a specific and potent inhibitor of GzmB activity, VTI-1002, resulted in significant improvements on skin affected by PDs.
Article content
While the supply of approved vaccines for the SARS-CoV-2 virus the strain of coronavirus that causes COVID-19 is limited, governments and health authorities are tasked with deciding who gets the vaccine first, second and last.
A number of competing priorities are considered, including minimizing deaths, stopping the spread of the virus and preserving the functionality of the health-care system.
We apologize, but this video has failed to load.
Try refreshing your browser, or COVID-19: How we decide who gets the vaccine first Back to video
To reduce mortality, the vaccine should be targeted to seniors, while slowing transmission means prioritizing young adults, experts say.